Table 2 Ongoing combination trials with DDR and immune checkpoint inhibitors (www.clinicaltrials.gov)

ICI	Tumour group	Target population	DDR agent	Phase	Arms	Planned n	Trial status	NCT	Citation/remarks
Durvalumab	Breast	3rd line	Olaparib	1/2	Olaparib + Durvalumab	133	Recruiting	NCT02734004
	Gastric	2nd line
	Ovarian	Platinum sensitive
	SCLC	2nd line
	NSCLC/ SCLC	2nd or higher line	Olaparib	1/2	Durvalumab + Olaparib	338	Recruiting	NCT02484404
	Breast	TNBC, < 3 prior lines			Durvalumab + Cediranib
	Ovarian	Platinum resistant			Durvalumab + Olaparib + Cediranib
	Colorectal	3rd line
	Prostate	mCRPC
	Ovary	gBRCA	Olaparib	1/2	Olaparib + Durvalumab + Tremelimumab	39	Not yet recruiting	NCT02953457
	NSCLC	Refractory	AZD6738	1	AZD6738 + Durvalumab	114	Recruiting	NCT02264678	Has other arms involving AZD 6738 with other agents
	HNSCC
Tremelimumab	Ovarian	2nd line +	Olaparib	1/2	Tremelimumab + Olaparib	50	Recruiting	NCT02571725	gBRCA only
Pembrolizumab	Breast	Up to 3 prior lines	Niraparib	1/2	niraparib + pembrolizumab	114	Recruiting	NCT02657889	TNBC only
	Ovarian	Up to 4 prior lines							Platinum resistant/refractory only
Nivolumab	NSCLC	1st line metastatic	Carboplatin + paclitaxel or pemetrexed + Veliparib	2	Veliparib + nivolumab + platinum doublet chemotherapy	184	Recruiting	NCT02944396	NA
					Veliparib + platinum doublet chemotherapy
	Adv solid tumours	Refractory to std therapy	Veliparib	1	Veliparib + Nivolumab	50	Not yet recruiting	NCT03061188
Atezolizumab	Breast	Any prior therapy allowed	Veliparib	2	Veliparib	90	Recruiting	NCT02849496	TNBC + gBRCA only
					Atezolizumab
					veliparib + atezolizumab
BGB-A317	Adv solid tumours	2nd line +	BGB-290	1	BGB-A317 + BGB-290	124	Recruiting	NCT02660034

Abbreviations: DDR=DNA damage response; gBRCA=germline BRCA; HNSCC=head and neck squamous cell cancer; ICI=immune checkpoint inhibitor; mCRPC=metastatic castration-resistant prostate cancer; NA=not available; NSCLC=non-small-cell lung cancer; SCLC=small-cell lung cancer; TNBC=triple-negative breast cancer.

Search